NR-E Toxicology Study

Completed and published in the International Journal of Toxicology. The results showed that Elysium’s proprietary nicotinamide riboside (NR-E) has a superior safety profile to all other consumer NR products.

Next up:

Non-Alcoholic Fatty Liver (NAFL)

Completed human clinical trial to study the effects of Basis on liver fat accumulation in healthy adults with fatty liver; results will be announced in 2021 and published by 2022.

Acute Kidney Injury (AKI) Phase I

Published in BMC Nephrology, the Phase I human clinical trial, conducted in partnership with Massachusetts General Hospital, enabled the FDA approval of an Investigational New Drug application for Basis and the AKI Phase II trial.

Acute Kidney Injury (AKI) Phase II

Initiated at Mayo Clinic, the human clinical trial will evaluate the efficacy of Basis for the prevention of AKI in patients that have undergone a cardiac surgery; primary study completion date October 2023.